Fox Run Management L.L.C. Makes New Investment in HealthEquity, Inc. $HQY

Fox Run Management L.L.C. bought a new stake in shares of HealthEquity, Inc. (NASDAQ:HQY) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,738 shares of the company’s stock, valued at approximately $915,000.

Other hedge funds have also made changes to their positions in the company. Envestnet Asset Management Inc. lifted its stake in HealthEquity by 12.1% in the first quarter. Envestnet Asset Management Inc. now owns 128,657 shares of the company’s stock valued at $11,369,000 after buying an additional 13,918 shares during the last quarter. Crossmark Global Holdings Inc. increased its holdings in shares of HealthEquity by 4.3% in the 1st quarter. Crossmark Global Holdings Inc. now owns 6,296 shares of the company’s stock worth $556,000 after acquiring an additional 261 shares during the period. Greenleaf Trust lifted its position in HealthEquity by 7.8% in the 1st quarter. Greenleaf Trust now owns 2,407 shares of the company’s stock valued at $213,000 after purchasing an additional 175 shares during the last quarter. Xponance Inc. boosted its stake in HealthEquity by 1.1% during the 1st quarter. Xponance Inc. now owns 12,412 shares of the company’s stock valued at $1,097,000 after purchasing an additional 136 shares during the period. Finally, New York State Common Retirement Fund grew its position in HealthEquity by 37.1% in the 1st quarter. New York State Common Retirement Fund now owns 140,155 shares of the company’s stock worth $12,385,000 after purchasing an additional 37,955 shares during the last quarter. Institutional investors own 99.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on HQY. Weiss Ratings restated a “hold (c+)” rating on shares of HealthEquity in a research report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price target on HealthEquity from $125.00 to $126.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 3rd. Barrington Research restated an “outperform” rating and set a $125.00 price objective on shares of HealthEquity in a research note on Friday, August 29th. Royal Bank Of Canada increased their target price on shares of HealthEquity from $109.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday, September 3rd. Finally, Jefferies Financial Group raised their target price on shares of HealthEquity from $130.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $121.31.

HealthEquity Trading Up 1.0%

Shares of HQY stock opened at $93.71 on Monday. The stock has a 50-day simple moving average of $93.25 and a 200 day simple moving average of $95.56. HealthEquity, Inc. has a fifty-two week low of $74.07 and a fifty-two week high of $116.65. The stock has a market capitalization of $8.07 billion, a P/E ratio of 56.79, a P/E/G ratio of 1.36 and a beta of 0.47. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.47.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Tuesday, September 2nd. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. HealthEquity had a net margin of 11.49% and a return on equity of 12.04%. The firm had revenue of $325.80 million for the quarter, compared to analysts’ expectations of $320.68 million. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. On average, sell-side analysts expect that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.

Insider Activity at HealthEquity

In other HealthEquity news, EVP Michael Henry Fiore sold 1,781 shares of the company’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $88.21, for a total value of $157,102.01. Following the transaction, the executive vice president owned 49,795 shares of the company’s stock, valued at approximately $4,392,416.95. This represents a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Delano Ladd sold 1,500 shares of the firm’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $92.07, for a total value of $138,105.00. Following the sale, the executive vice president directly owned 76,979 shares of the company’s stock, valued at approximately $7,087,456.53. This represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 9,281 shares of company stock valued at $859,867. Company insiders own 1.50% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.